Fractyl Health, Inc. (GUTS) Stock Ticker
Market factors today
Unlock the full GUTS picture
About Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
GUTS stock facts
| Ticker symbol | GUTS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $74.7M |
| CEO | Harith Rajagopalan |
| Employees | 100 |
| Headquarters | Burlington, MA, US |
| IPO date | 2024-02-02 |
| Website | fractyl.com |
What you can see for GUTS on Tickr
Live GUTS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GUTS report.
Rankings
GUTS peers
FAQ
What is the ticker symbol for Fractyl Health, Inc.?
The ticker symbol for Fractyl Health, Inc. is GUTS, listed on the NASDAQ.
What is GUTS?
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel…